AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou

Press/Media: Press / Media

PeriodAug 3 2017

Media coverage

2

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou
    Media name/outletPR Newswire
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou
    Media name/outletPR Newswire
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad